Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

11/05/2015 - 2 minutes

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest of two giants for its pipeline.

Galapagos’ pipeline includes three Phase II programs, two Phase I trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. Regarding the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1 (Janus kinase inhibitor) for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. Drugs that inhibit the activity of these Janus kinases, block cytokine signaling and, ultimately, inflammation. Filgotinib is currently in Phase IIb in rheumatoid arthritis and in Phase II in Crohn’s disease. Galapagos reported good activity and a favorable safety profile after monitoring both studies for 12 weeks.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member